Wave, Life Sciences
Wave Life Sciences (NASDAQ:WVE) PT Raised to $22.00
Wave Life Sciences (NASDAQ:WVE – Get Free Report) had its price objective upped by Leerink Partners from $20.00 to $22.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock.
Wave Life Sciences Stock Climbs on RNA Editing Progress
Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of patients with a genetic disorder that can lead to lung or liver disease. T
Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed.
Shares of Wave Life Sciences surged Wednesday after the company announced "impressive" proof-of-concept results for its new technology.
Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Positive Outlook for Wave Life Sciences Driven by Promising RNA Editing Data and Strategic Opportunities
Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed’s rating is
Wave Life Sciences Shares Surge After RNA Editing Discovery
Wave's RNA editing technology appears to have highly potential for the treatment of AATD, a genetic disorder with potential life threatening and implicating the lungs and liver. As recently demonstrated in a Phase I and II concept trial,
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE stock's potential in this $10B market.
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license rights with $525 million in milestone potential.
Wave Life Sciences: Buy Rating Affirmed on Promising RNA Editing Platform Data
Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The
RNA-editing stocks soar on Wave Life’s breakthrough trial data
Companies developing RNA-editing therapies are rallying Wednesday after breakthrough data from a clinical trial showed the technology’s promise as a treatment. Wave Life Sciences Ltd. said it achieved so-called proof-of-mechanism in a single-dose trial of its potential treatment for a genetic disorder that causes lung and liver diseases.
Looking At WAVE Life Sciences's Recent Unusual Options Activity
In terms of liquidity and interest, the mean open interest for WAVE Life Sciences options trades today is 608.71 with a total volume of 10,303.00.
Wave Life Sciences: Increased Probability of Success Drives Buy Rating Amid Platform Advancements
Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on Wave Life Sciences (WVE – Research Report) and increased the price target ...
FierceBiotech1d
Wave hails first for human RNA editing with GSK-partnered prospect, sending stock skyward
Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...
biopharma-reporter18h
Wave claims first clinical RNA editing title in rare genetic disease
Wave Life Sciences reports that it has successfully carried out RNA editing in two patients with alpha-1 antitrypsin ...
Takeda declines to exercise option for Wave's WVE-003
Wave Life Sciences (WVE) said Takeda (TAK) has elected not to exercise its option to further develop its Huntington’s disease ...
FierceBiotech1d
Goodbye Wave: Takeda axes Huntington’s pact, freeing partner to pursue fresh interest
Takeda is walking away from the last target in a collaboration with Wave Life Scien | Takeda has brandished a termination ...
BRIEF-Wave Life Sciences Units Were Notified That Takeda Did Not Intend To Exercise, Thus Elected To Terminate Option For Huntingtin Target
UNITS WERE NOTIFIED THAT TAKEDA DID NOT INTEND TO EXERCISE, THUS ELECTED TO TERMINATE OPTION FOR HUNTINGTIN TARGET * WAVE LIFE SCIENCES - SINCE INCEPTION OF PARTIES' COLLABORATION, TAKEDA HAS PAID WAV ...